Viz.ai is a healthcare technology company founded in 2016 that specializes in artificial intelligence-based software for medical imaging analysis and clinical workflow optimization. The company’s primary focus is on stroke care and cardiovascular disease detection, utilizing deep learning algorithms to analyze CT scans and other medical images. The company’s flagship product, the Viz LVO platform, is FDA-cleared and uses AI to automatically detect large vessel occlusions (LVOs) in stroke patients and notify relevant medical professionals. This technology helps reduce the time between imaging and treatment, which is crucial in stroke care where “time is brain.” Viz.ai’s software suite has expanded to include solutions for pulmonary embolism, aortic disease, and cerebral aneurysms. The platform integrates with hospital systems and enables synchronized communication among care team members through mobile and desktop applications. The company has secured significant funding through multiple investment rounds, including a $100 million Series D round in 2022, reaching a valuation of over $1 billion. Viz.ai has partnerships with numerous healthcare systems across the United States and Europe, and its technology is used in hundreds of hospitals. The company has received several regulatory clearances, including FDA 510(k) clearances and CE Mark approval for various applications.